Annalisa Savardi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Annalisa Savardi has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Laura Cancedda
Brain Development and Disease Laboratory, Istituto Italiano di Tecnologia, Genoa, Italy
5 shared publications Amos Fumagalli
2 shared publications- Andrea Contestabile
Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy
2 shared publications - Andrea Petretto
Core Facility for Omics Sciences, IRCCS Istituto Giannina Gaslini, Genoa, Italy
2 shared publications Bruno Pinto
BIO@SNS, Scuola Normale Superiore, Piazza dei Cavalieri 7, 56126 Pisa, Italy; Brain Development and Disease Laboratory, Istituto Italiano di Tecnologia, via Morego 30, 16163 Genova, Italy
2 shared publications- Marco Borgogno
IAMA Therapeutics, via Filippo Turati 2/9, 16128 Genoa, Italy
2 shared publications
Latest Publications
- Open Access
- 1 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (9) , eadk8123
Early IGF-1 receptor inhibition in mice mimics preterm human brain disorders and reveals a therapeutic target
Besides recent advances in neonatal care, preterm newborns still develop sex-biased behavioral alterations. Preterms fail to receive placental insulin-like growth factor-1 (IGF-1), a major fetal growth hormone in utero, and low IGF-1 serum levels correlate with preterm poor neurodevelopmental outcomes. Here, we mimicked IGF-1 deficiency of preterm newborns in mice by perinatal administration of an IGF-1 receptor antagonist. This resulted in sex-biased brain microstructural, functional, and behavioral alterations, resembling those of ex-preterm children, which we characterized performing parallel mouse/human behavioral tests. Pharmacological enhancement of GABAergic tonic inhibition by the U.S. Food and Drug Administration–approved drug ganaxolone rescued functional/behavioral alterations in mice. Establishing an unprecedented mouse model of prematurity, our work dissects the mechanisms at the core of abnormal behaviors and identifies a readily translatable therapeutic strategy for preterm brain disorders.
- 1 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (9) , eadk8123
Open AccessEarly IGF-1 receptor inhibition in mice mimics preterm human brain disorders and reveals a therapeutic target
Besides recent advances in neonatal care, preterm newborns still develop sex-biased behavioral alterations. Preterms fail to receive placental insulin-like growth factor-1 (IGF-1), a major fetal growth hormone in utero, and low IGF-1 serum levels correlate with preterm poor neurodevelopmental outcomes. Here, we mimicked IGF-1 deficiency of preterm newborns in mice by perinatal administration of an IGF-1 receptor antagonist. This resulted in sex-biased brain microstructural, functional, and behavioral alterations, resembling those of ex-preterm children, which we characterized performing parallel mouse/human behavioral tests. Pharmacological enhancement of GABAergic tonic inhibition by the U.S. Food and Drug Administration–approved drug ganaxolone rescued functional/behavioral alterations in mice. Establishing an unprecedented mouse model of prematurity, our work dissects the mechanisms at the core of abnormal behaviors and identifies a readily translatable therapeutic strategy for preterm brain disorders.
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S84
EARLY-IN-LIFE INTERVENTIONS TARGETING NKCC1 RESCUE THE ALTERED GABAERGIC SIGNALING AND THE EPILEPTIC AND LOCOMOTOR DEFICITS IN THE ADULT DS MICE
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S84
Open AccessEARLY-IN-LIFE INTERVENTIONS TARGETING NKCC1 RESCUE THE ALTERED GABAERGIC SIGNALING AND THE EPILEPTIC AND LOCOMOTOR DEFICITS IN THE ADULT DS MICE
- 4 January 2023
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 6 (1) , 1-11
Preclinical Development of the Na-K-2Cl Co-transporter-1 (NKCC1) Inhibitor ARN23746 for the Treatment of Neurodevelopmental Disorders
Alterations in the expression of the Cl- importer Na-K-2Cl co-transporter-1 (NKCC1) and the exporter K-Cl co-transporter 2 (KCC2) lead to impaired intracellular chloride concentration in neurons and imbalanced excitation/inhibition in the brain. These alterations have been observed in several neurological disorders (e.g., Down syndrome and autism). Recently, we have reported the discovery of the selective NKCC1 inhibitor "compound ARN23746" for the treatment of Down syndrome and autism in mouse models. Here, we report on an extensive preclinical characterization of ARN23746 toward its development as a clinical candidate. ARN23746 shows an overall excellent metabolism profile and good brain penetration. Moreover, ARN23746 is effective in rescuing cognitive impairment in Down syndrome mice upon per os administration, in line with oral treatment of neurodevelopmental disorders. Notably, ARN23746 does not present signs of toxicity or diuresis even if administered up to 50 times the effective dose. These results further support ARN23746 as a solid candidate for clinical trial-enabling studies.
- 4 January 2023
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 6 (1) , 1-11
Preclinical Development of the Na-K-2Cl Co-transporter-1 (NKCC1) Inhibitor ARN23746 for the Treatment of Neurodevelopmental Disorders
Alterations in the expression of the Cl- importer Na-K-2Cl co-transporter-1 (NKCC1) and the exporter K-Cl co-transporter 2 (KCC2) lead to impaired intracellular chloride concentration in neurons and imbalanced excitation/inhibition in the brain. These alterations have been observed in several neurological disorders (e.g., Down syndrome and autism). Recently, we have reported the discovery of the selective NKCC1 inhibitor "compound ARN23746" for the treatment of Down syndrome and autism in mouse models. Here, we report on an extensive preclinical characterization of ARN23746 toward its development as a clinical candidate. ARN23746 shows an overall excellent metabolism profile and good brain penetration. Moreover, ARN23746 is effective in rescuing cognitive impairment in Down syndrome mice upon per os administration, in line with oral treatment of neurodevelopmental disorders. Notably, ARN23746 does not present signs of toxicity or diuresis even if administered up to 50 times the effective dose. These results further support ARN23746 as a solid candidate for clinical trial-enabling studies.
- Open Access
- 17 June 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (14) , 10203-10229
Design, Synthesis, In Vitro and In Vivo Characterization of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in Down Syndrome
Intracellular chloride concentration [Cl–]i is defective in several neurological disorders. In neurons, [Cl–]i is mainly regulated by the action of the Na+–K+–Cl– importer NKCC1 and the K+–Cl– exporter KCC2. Recently, we have reported the discovery of ARN23746 as the lead candidate of a novel class of selective inhibitors of NKCC1. Importantly, ARN23746 is able to rescue core symptoms of Down syndrome (DS) and autism in mouse models. Here, we describe the discovery and extensive characterization of this chemical class of selective NKCC1 inhibitors, with focus on ARN23746 and other promising derivatives. In particular, we present compound 40 (ARN24092) as a backup/follow-up lead with in vivo efficacy in a mouse model of DS. These results further strengthen the potential of this new class of compounds for the treatment of core symptoms of brain disorders characterized by the defective NKCC1/KCC2 expression ratio.
- 17 June 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (14) , 10203-10229
Open AccessDesign, Synthesis, In Vitro and In Vivo Characterization of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in Down Syndrome
Intracellular chloride concentration [Cl–]i is defective in several neurological disorders. In neurons, [Cl–]i is mainly regulated by the action of the Na+–K+–Cl– importer NKCC1 and the K+–Cl– exporter KCC2. Recently, we have reported the discovery of ARN23746 as the lead candidate of a novel class of selective inhibitors of NKCC1. Importantly, ARN23746 is able to rescue core symptoms of Down syndrome (DS) and autism in mouse models. Here, we describe the discovery and extensive characterization of this chemical class of selective NKCC1 inhibitors, with focus on ARN23746 and other promising derivatives. In particular, we present compound 40 (ARN24092) as a backup/follow-up lead with in vivo efficacy in a mouse model of DS. These results further strengthen the potential of this new class of compounds for the treatment of core symptoms of brain disorders characterized by the defective NKCC1/KCC2 expression ratio.
- Open Access
- 1 September 2018
- Published by Elsevier in Progress in Neurobiology
- Vol. 168, 69-85
In vivo methods for acute modulation of gene expression in the central nervous system
- 1 September 2018
- Published by Elsevier in Progress in Neurobiology
- Vol. 168, 69-85
Open AccessIn vivo methods for acute modulation of gene expression in the central nervous system
- Open Access
- 1 December 2017
- Published by Elsevier in Cell Reports
- Vol. 21 (12) , 3596-3611
APache Is an AP2-Interacting Protein Involved in Synaptic Vesicle Trafficking and Neuronal Development
- 1 December 2017
- Published by Elsevier in Cell Reports
- Vol. 21 (12) , 3596-3611
Open AccessAPache Is an AP2-Interacting Protein Involved in Synaptic Vesicle Trafficking and Neuronal Development